The role of gut microbiota for response prediction and efficacy improvement of anti-PD1/PDL1 immunotherapy

The Role of Gut Microbiota for Response Prediction and Efficacy Improvement of
anti-PD1/PDL1 Immunotherapy

Date:

Monday, 26 July 2021

Time:

8:00 a.m. Chennai
10:30 a.m. Singapore
11:30 a.m. Seoul, Tokyo
12:30 p.m. Melbourne

Research Objective:

Anti-PD-1/PD-L1 immunotherapy is promising for late-stage lung cancer treatment, however, the response rate needs to be improved. Gut microbiota plays a crucial role in immunotherapy sensitization and Panax ginseng has been shown to possess immunomodulatory potential. In this study, we aimed to investigate whether the combination treatment of ginseng polysaccharides (GPs) and αPD-1 mAb could sensitize the response by modulating gut microbiota.

Design:

Syngeneic mouse models were administered GPs and αPD-1 mAb, and the sensitizing anti-tumor effects of the combination treatment on gut microbiota were further assessed by fecal microbiota transplantation (FMT) and 16S rRNA sequencing. To assess the immune-related metabolites, metabolomics analysis of the plasma samples was performed.

Attend this webinar to hear from:

Dr. Elaine Leung in demonstrating the "results that GPs combined with αPD-1 mAb may be a new strategy to sensitize lung cancer patients to anti-PD-1 immunotherapy. The gut microbiota can be used as a novel biomarker to predict the response to anti-PD-1 immunotherapy".
Dr. Mark Driscoll on delivering a "Live Software Demo: Shoreline Biome SBanalyzer and PacBio Long Read Data Enable Strain Level Bacterial Fingerprinting from Microbiome Samples".
Dr. Khi Pin Chua on presenting a "Bioinformatics Workflow for HiFi Metagenomics".

PacBio Webinar Series

The Role of Gut Microbiota for Response Prediction and Efficacy Improvement of
anti-PD1/PDL1 Immunotherapy

Speakers

The Role of Gut Microbiota for Response Prediction and Efficacy Improvement of anti-PD1/PDL1 Immunotherapy

Speakers

The Role of Gut Microbiota for Response Prediction and Efficacy Improvement of
anti-PD1/PDL1 Immunotherapy